For those who have asked: Here is Dr. Siskin's FDA approved clinical trial information, which began in 2010. It was suggested that he recruit a couple hundred individuals with MS who would undergo venoplasty for CCSVI, who met the trial requirements, who would not know if they had been treated-- in order for results to be "statistically significant." Realize that the BNAC trial, which was NOT FDA approved, only had 16 people undergo venoplasty, yet it is being held up as the definitive double-blind trial. Is this right?


Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI)...
clinicaltrials.gov
The study is being done to determine if venous angioplasty is an effective treatment for chronic cerebrospinal venous insufficiency (CCSVI). In this condition, areas of narrowing or blockages are present in the internal jugular or azygos veins (veins which drain blood from the central nervous system...